(NASDAQ: IPA) Immunoprecise Antibodies's forecast annual revenue growth rate of 21.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Immunoprecise Antibodies's revenue in 2025 is $17,897,810.On average, 1 Wall Street analysts forecast IPA's revenue for 2026 to be $1,039,390,737, with the lowest IPA revenue forecast at $1,039,390,737, and the highest IPA revenue forecast at $1,039,390,737. On average, 1 Wall Street analysts forecast IPA's revenue for 2027 to be $1,273,392,116, with the lowest IPA revenue forecast at $1,273,392,116, and the highest IPA revenue forecast at $1,273,392,116.
In 2028, IPA is forecast to generate $1,457,547,046 in revenue, with the lowest revenue forecast at $1,457,547,046 and the highest revenue forecast at $1,457,547,046.